Resource Center
In our latest white paper, we detail the analytical validation of our hybrid capture sequencing assay for detecting invasive fungal and bacterial infections (IFBIs) from plasma and BAL samples. Our assay demonstrated high sensitivity and specificity, with strong concordance to qPCR and fewer polymicrobial results. This targeted approach enhances diagnostic clarity and supports better outcomes for immunocompromised patients.
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.